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ABSTRACT
Introduction: This sub-analysis of the A1chieve
study aimed to examine the safety and efficacy
of insulin detemir (IDet) initiation over
24 weeks in relation to baseline body mass
index (BMI) in people with type 2 diabetes
mellitus (T2DM).
Methods: A1chieve was a 24-week non-
interventional study to assess the safety and
efficacy of insulin analogs in routine practice.
This sub-analysis included insulin-naı¨ve
patients who initiated IDet therapy based on
their physicians’ decision. Patients were
stratified according to baseline BMI (Group I,
\25.0 kg/m2; Group II, 25.0 to \30.0 kg/m2;
Group III, 30.0 to \35.0 kg/m2; Group IV
C35.0 kg/m2). Safety and efficacy variables
were assessed over 24 weeks.
Results: Overall, 10,650 insulin-naı¨ve patients
were included (3,045 patients in Group I, 4,186
patients in Group II, 2,365 patients in Group III,
and 1,054 patients in Group IV). Four serious
adverse drug reactions (SADRs) were reported.
From baseline to Week 24, there was no
statistically significant difference in the
proportion of patients reporting overall
hypoglycemia in Group I (4.0% vs. 4.4%),
while a significant decrease in Group II (4.8%
vs. 4.0%, p = 0.0335) and significant increases
Trial registration number: NCT00869908.
Electronic supplementary material The online
version of this article (doi:10.1007/s13300-014-0054-2)
contains supplementary material, which is available to
authorized users.
M. E. Khamseh (&)
Endocrine Research Center, Institute of
Endocrinology and Metabolism, Iran University
of Medical Sciences, Tehran, Iran
e-mail: khamseh.m@iums.ac.ir
V. Prusty
Novo Nordisk Intl Operations, Zurich, Switzerland
Z. Latif
Bangladesh Institute of Research and Rehabilitation
in Diabetes, Endocrine and Metabolic Disorders
(BIRDEM) Hospital, Dhaka, Bangladesh
G. Gonzalez-Galvez
Instituto Jalisciense de Investigacio´n en Diabetes
y Obesidad S. C., Guadalajara, Jal., Mexico
G. Dieuzeide
Centro de Atencio´n Integral en Diabetes,
Endocrinologı´a y Metabolismo (CAIDEM.R.E.),
Buenos Aires, Argentina
A. Zilov
First Moscow State Medical University na I.M.
Sechenov, Moscow, Russia
Diabetes Ther (2014) 5:127–140
DOI 10.1007/s13300-014-0054-2
in Groups III and IV (3.3% vs. 5.4% and 3.4% vs.
7.0%, respectively, p\0.001) were noted. The
mean body weight increased from baseline to
Week 24 in Group I (60.7 ± 8.4 vs.
61.8 ± 8.5 kg) and reduced in Groups II, III,
and IV (74.5 ± 9.2 vs. 74.2 ± 9.2 kg, 87.4 ± 10.3
vs. 86.0 ± 9.8 kg, and 102.2 ± 14.3 vs.
100.1 ± 14.2 kg, respectively; all p\0.001).
Significant improvements were noted in
glycemic parameters, systolic blood pressure,
and lipids over 24 weeks, irrespective of baseline
BMI status.
Conclusion: IDet therapy was associated with
improved glycemic control and a low number of
SADRs. Greater weight loss was observed with
higher BMI.
Keywords: A1chieve; Body mass index (BMI);
Body weight; Hypoglycemia; Insulin detemir
(IDet); Type 2 diabetes
INTRODUCTION
The main goal of type 2 diabetes mellitus (T2DM)
management is to safely improve glycemic
control [1]. The joint guidelines of the
American Diabetes Association (ADA) and the
European Association for the Study of Diabetes
(EASD) recommend maintaining glycated
hemoglobin A1c (HbA1c) levels \7.0%
(\53 mmol/mol) for good glycemic control in
patients with T2DM [2]. The guidelines also
recommend a stepwise pathway for the
initiation and subsequent intensification of oral
glucose-lowering drugs (OGLDs) and insulin to
combat the progressive nature of T2DM [2].
However, despite these recommendations,
many T2DM patients continue to experience
poor glycemic control in real-life settings [3].
Weight gain is a common consequence of
intensified pharmacological therapy in T2DM
[4]. Approximately 80% of patients with T2DM
are either overweight [body mass index (BMI)
25.0–29.9 kg/m2] or obese (BMI[30.0 kg/m2)
[2]. Insulin is the most effective treatment for
T2DM; however, possible weight gain resulting
from insulin use is regarded as a major barrier to
the initiation of insulin by many patients and
physicians alike [5] and may be the cause of
delayed insulin initiation in T2DM patients
who are already overweight or obese [6]. It is,
therefore, important to determine the potential
impact of baseline BMI status on T2DM
management strategies and patient outcomes
in clinical practice.
The basal insulin analog, insulin detemir
(IDet), is known to be safe and efficacious in
the management of T2DM and induces less
weight gain compared to treatment with other
basal insulins, such as neutral protamine
Hagedorn (NPH) insulin and insulin glargine
[7]. IDet differs from endogenous insulin in that
threonine has been deleted at position B30 and a
myristic acid side chain is attached to the lysine
residue at position B29 of the insulin molecule
[8]. Due to these structural modifications, IDet
molecules have a strong tendency to self-
associate and are highly bound to albumin in
the subcutaneous depot, resulting in prolonged
therapeutic action. A pooled analysis examining
data from 900 T2DM patients treated with either
IDet or NPH insulin in a basal-bolus regimen by
Raslova´ et al. [9] demonstrated that patients on
IDet therapy gained less weight compared to
those on NPH insulin and the weight-limiting
effect increased with baseline BMI.
The mechanism underlying the low weight
gain noted with IDet therapy is currently
unconfirmed [10]. It is possible that the low
glucose variability associated with IDet therapy
minimizes defensive snacking thereby limiting
weight gain. It has also been hypothesized that
IDet may have a positive effect on satiety
signaling in the central nervous system [10],
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while another theory proposes that IDet may
have a role in suppressing adipogenesis in the
peripheral tissues due to its albumin-binding
tendencies that promote greater exposure to
hepatocytes than to peripheral tissues [10].
This sub-analysis of the A1chieve study [11]
aimed to examine the safety and efficacy of IDet
therapy in T2DM management in relation to
baseline BMI in a heterogeneous cohort of
insulin-naı¨ve patients. It is important to
explore whether T2DM management practices
are affected by baseline BMI status and also to
determine whether the weight-limiting effects
of IDet therapy in relation to baseline BMI are
sustained in real-life clinical practice.
MATERIALS AND METHODS
Study Design
A1chieve was a 24-week, open-label,
multinational, non-interventional study to
evaluate the clinical safety and efficacy of IDet
(Levemir, Novo Nordisk, Denmark), biphasic
insulin aspart 30 (NovoMix 30, Novo Nordisk,
Denmark), and insulin aspart (NovoRapid,
Novo Nordisk, Denmark), alone or in
combination, in the treatment of T2DM in
routine clinical care [11]. Patients were
recruited between January 2009 and June 2010
from 3,166 centers across 28 countries in 7
regions. The regions were China, East Asia
(Indonesia, Korea, Malaysia, Philippines,
Singapore, Taiwan), Latin America (Argentina,
Mexico), Middle East ? Gulf (Bahrain, Egypt,
Iran, Jordan, Kuwait, Oman, Qatar, Saudi
Arabia, Turkey, UAE, Yemen), North Africa
(Algeria, Libya, Morocco, Tunisia), Russia, and
South Asia (Bangladesh, India, Pakistan). This
paper reports the safety and efficacy of IDet
therapy in relation to baseline BMI in insulin-
naı¨ve patients in the overall A1chieve cohort.
The A1chieve study design has been
described in full previously by Home et al.
[11]. Briefly, the decision to prescribe IDet was
made by the physicians in routine clinical
practice. IDet was commercially available and
used in accordance with local regulatory
standards. Due to the non-interventional
approach of this study, there were no defined
study procedures and all assessments were made
by physicians during routine clinical visits. Data
for analysis from the physicians’ clinical notes
and patients’ recall and self-monitoring diary/
blood glucose meter were collected at baseline,
Week 12 and Week 24 and transferred to a
standard case report form (CRF). Concomitant
OGLD use was also directed by the physicians.
Patients
Insulin-naı¨ve patients initiating treatment with
IDet within 4 weeks prior to the start of the study
were included in this sub-analysis. Any patient
who had been treated with the study insulins for
over 4 weeks before the start of the study or who
had a hypersensitivity to any of the insulins was
excluded. Women who were pregnant,
breastfeeding or intended to become pregnant
within 6 months from the start of the study
were also excluded. All procedures followed were
in accordance with the ethical standards
of the responsible committee on human
experimentation (institutional and national of
the participating countries) and with the Helsinki
Declaration of 1975, as revised in 2008. Informed
consent was obtained from all patients for being
included in the study.
Variables and Assessments
The primary variable was the incidence of
serious adverse drug reactions (SADRs),
including major hypoglycemic events.
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Secondary variables included the change in
the proportion of patients reporting
hypoglycemic events in the last 4 weeks before
baseline and before the final visit (Week 24),
and the change from baseline to Week 24 in
HbA1c, fasting plasma glucose (FPG),
postprandial plasma glucose (PPPG), body
weight, systolic blood pressure (SBP), lipids
[total cholesterol, triglycerides, high-density
lipoprotein (HDL) cholesterol, and low-density
lipoprotein (LDL) cholesterol], and quality of
life (QoL).
A hypoglycemic event was defined as an
event with symptoms of hypoglycemia that
resolved with oral carbohydrate intake,
glucagon or intravenous glucose, or any
symptomatic or asymptomatic plasma glucose
measurement \3.1 mmol/L or 56 mg/dL.
Nocturnal hypoglycemic events were
defined as individualized symptomatic events
consistent with hypoglycemia, that occurred
while the patient was asleep, between bedtime
after the evening insulin injection and
before getting up in the morning [if relevant;
before morning determination of fasting
plasma glucose (FPG) and before morning
injection].
Major hypoglycemic events were defined as
events with severe central nervous system
symptoms consistent with hypoglycemia
in which the patient was unable to treat
himself/herself and had either plasma
glucose \3.1 mmol/L or 56 mg/dL, or reversal
of symptoms after either food intake
or glucagon or intravenous glucose
administration.
The EuroQol Visual Analogue Scale (EQ-VAS)
was used to rate an individual’s current health-
related QoL state on a scale of 0 (worst score) to
100 (best score) based on responses to the
EuroQol-5 Dimension questionnaire that
evaluates mobility, anxiety/depression, pain/
discomfort, self-care and usual activity.
Statistical Methods
Patients were stratified by baseline BMI intervals
(Group I, \25.0 kg/m2; Group II, 25.0
to \30.0 kg/m2; Group III, 30.0 to \35.0 kg/
m2; and Group IV, C35.0 kg/m2). Continuous
and discrete variables were summarized using
descriptive statistics (mean, SD) and frequency
tables (n, %), respectively.
The change in the proportion of patients
reporting at least one event of hypoglycemia in
the 4 weeks before study visits was analyzed
using McNemar’s test. The change from
baseline to Week 24 in HbA1c, FPG, PPPG,
body weight, SBP, lipids, and QoL was
analyzed using a paired t test. Two-sided
testing with a 5% significance level was used
(a = 0.05).
Data analysis was performed by Novo
Nordisk using SAS (Version 9.1.3).
RESULTS
Patient Disposition and Baseline
Demographics
Overall, 12,078 insulin-naı¨ve patients initiated
IDet therapy; however, baseline BMI data was
missing for 1,428 patients. Therefore, this sub-
analysis included 10,650 patients, who initiated
IDet therapy. No other insulin therapy was
administered during the 24-week study. Patient
characteristics for the entire cohort, stratified by
baseline BMI intervals, are presented in Table 1.
The mean baseline HbA1c level was high
across all four groups (Table 1). Over 97.0% of
patients initiated IDet therapy to improve
glycemic control across all groups.
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The most commonly used OGLDs in each
group at pre-study (prior to study enrolment),
baseline and Week 24 are presented in Table 2.
At pre-study, baseline and Week 24, a higher
proportion of patients with a higher baseline
BMI were on more than two OGLDs.
Insulin Dose and Dosing Frequency
The mean total daily insulin dose, dose by body
weight and dosing frequency are presented in
Table 3.
At baseline, the mean insulin dose by weight
was lowest in Group IV (0.20 ± 0.12 U/kg). At
Week 24, the mean insulin dose by weight was
observed to be similar across the four groups
(Group I, 0.36 ± 0.18 U/kg; Group II, 0.35 ± 0.19
U/kg; Group III, 0.35 ± 0.18 U/kg; Group IV,
0.35 ± 0.18 U/kg), while the total daily insulin
dose was noted to increase with increasing
BMI (Group I, 21.8 ± 11.4 U/day; Group II,
25.9 ± 14.2 U/day; Group III, 29.9 ± 15.6
U/day; Group IV, 34.8 ± 18.9 U/day).
The majority of patients ([75.0%) in all four
groups followed once-daily dosing at baseline
and Week 24.
SADRs and Hypoglycemia
A total of 4 SADRs, all considered probably
related to IDet therapy, were reported: 1 event
of hyperglycemia in Group I, and 2 events of
hypoglycemia and 1 event of hyperglycemia in
Group II.
In Group I, there was no statistically
significant difference in the proportion of
patients reporting overall hypoglycemia from
the 4 weeks preceding baseline to the 4 weeks
preceding the final visit (4.0% vs. 4.4%,
Table 4). In Group II, a significant decrease
was noted in the proportion of patients
reporting overall hypoglycemia from the
4 weeks preceding baseline to the 4 weeks
preceding the final visit (4.8% vs. 4.0%,
p = 0.0335), while in Groups III and IV,
significant increases were noted in the
proportion of patients reporting overall
hypoglycemia from the 4 weeks preceding
baseline to the 4 weeks preceding the final
visit (3.3% vs. 5.4% and 3.4% vs. 7.0%,
respectively, both p\0.001).
During the 4 weeks preceding the final visit,
only 1 event of major hypoglycemia was
Table 1 Demographics and baseline characteristics by baseline BMI
Baseline BMI group (kg/m2)
<25.0 25.0 to <30.0 30.0 to <35.0 ‡35.0
N 3,045 4,186 2,365 1,054
Male/female (%) 57.1/42.9 60.6/39.4 48.9/51.1 39.6/60.4
Age (years) 55.6 ± 12.2 53.5 ± 11.1 52.7 ± 10.4 52.6 ± 10.1
Duration of T2DM (years) 8.1 ± 6.3 7.5 ± 5.3 7.5 ± 4.8 7.7 ± 4.8
Duration on OGLDs (years) 7.1 ± 5.9 6.8 ± 5.2 6.8 ± 4.7 7.0 ± 4.6
HbA1c (%/mmol/mol) 9.6 ± 1.8/81 ± 20 9.4 ± 1.6/79 ± 17 9.4 ± 1.4/79 ± 15 9.7 ± 1.6/83 ± 17
BMI (kg/m2) 22.5 ± 2.0 27.4 ± 1.4 32.2 ± 1.4 38.8 ± 3.6
Body weight (kg) 60.7 ± 8.4 74.5 ± 9.2 87.4 ± 10.3 102.2 ± 14.3
Data are mean ± SD or as stated
BMI body mass index, HbA1c glycated hemoglobin A1c, OGLD oral glucose-lowering drug, T2DM type 2 diabetes mellitus
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reported in Group IV. Incidence rates of minor
and nocturnal hypoglycemia were observed to
be directly proportional to BMI in the 4 weeks
preceding the final visit (Table 4).
Glycemic Control, Body Weight and SBP
Significant reductions in HbA1c, FPG and PPPG
were observed in all four groups after 24 weeks
(Table 5). At Week 24, the mean reductions in
HbA1c, FPG and PPPG were similar across
groups.
More patients met the HbA1c target of\7.0%
(\53 mmol/mol) at Week 24 compared to
baseline in all four groups [Group I, 75 (3.1%)
at baseline vs. 628 (30.8%) at Week 24; Group II,
66 (1.8%) at baseline vs. 1,086 (32.9%) at Week
24; Group III, 32 (1.5%) at baseline vs. 701
Table 2 Oral glucose-lowering drugs used at pre-study, baseline and Week 24
Time point OGLDs, n (%) Baseline BMI group (kg/m2)
<25.0 25.0 to <30.0 30.0 to <35.0 ‡35.0
Pre-study n 2,794 3,991 2,272 1,022
Metformin 2,128 (76.2) 3,426 (85.8) 2,044 (90.0) 937 (91.7)
Sulfonylureas 2,238 (80.1) 3,374 (84.5) 2,014 (88.6) 926 (90.6)
Thiazolidinediones 483 (17.3) 864 (21.6) 625 (27.5) 312 (30.5)
1 OGLDa 690 (24.7) 598 (15.0) 234 (10.3) 90 (8.8)
2 OGLDsa 1,484 (53.1) 2,362 (59.2) 1,310 (57.7) 563 (55.1)
[2 OGLDsa 620 (22.2) 1,031 (25.8) 728 (32.0) 369 (36.1)
Baseline n 2,621 3,850 2,231 1,004
Metformin 1,854 (70.7) 3,128 (81.2) 1,940 (87.0) 909 (90.5)
Sulfonylureas 1,599 (61.0) 2,496 (64.8) 1,651 (74.0) 762 (75.9)
Thiazolidinediones 292 (11.1) 465 (12.1) 269 (12.1) 171 (17.0)
1 OGLDa 1,209 (46.1) 1,427 (37.1) 596 (26.7) 212 (21.1)
2 OGLDsa 1,156 (44.1) 2,009 (52.2) 1,358 (60.9) 605 (60.3)
[2 OGLDsa 256 (9.8) 414 (10.8) 277 (12.4) 187 (18.6)
Week 24 n 2,252 3,427 2,072 918
Metformin 1,706 (75.8) 2,845 (83.0) 1,860 (89.8) 856 (93.2)
Sulfonylureas 1,300 (57.7) 2,155 (62.9) 1,441 (69.5) 654 (71.2)
Thiazolidinediones 203 (9.0) 339 (9.9) 244 (11.8) 148 (16.1)
1 OGLDa 1,052 (46.7) 1,325 (38.7) 553 (26.7) 205 (22.3)
2 OGLDsa 1,004 (44.6) 1,748 (51.0) 1,238 (59.7) 528 (57.5)
[2 OGLDsa 196 (8.7) 354 (10.3) 281 (13.6) 185 (20.2)
‘Pre-study’ is deﬁned as the period prior to study enrolment. Data are represented as n (%), or as stated
BMI body mass index, OGLD oral glucose-lowering drug, n the number of patients that were on OGLDs
a OGLDs used also included exenatide, DPP-4 inhibitors, glucosidase inhibitors and glinides
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(34.2%) at Week 24; Group IV, 14 (1.4%) at
baseline vs. 292 (31.4%) at Week 24].
After 24 weeks, a significant increase
in body weight was noted in Group I
(1.0 ± 3.2 kg), while significant decreases
were observed in the remaining three groups
(all p\0.001, Table 5). Greater weight
reductions were observed with high BMI
(Group II, -0.3 ± 3.5 kg; Group III, -1.4 ±
4.3 kg; Group IV, -2.2 ± 5.0 kg).
The mean SBP improved markedly across all
groups (all p\0.001, Table 5).
Table 3 Insulin dose and dosing frequency at baseline and Week 24 by baseline BMI
Baseline BMI group (kg/m2)
<25.0 25.0 to <30.0 30.0 to <35.0 ‡35.0
Insulin dose (U/day)
n 3,045 4,186 2,365 1,054
Baselinea 15.8 ± 7.8 18.1 ± 9.7 18.9 ± 10.8 20.8 ± 12.8
Week 24a 21.8 ± 11.4 25.9 ± 14.2 29.9 ± 15.6 34.8 ± 18.9
Insulin dose (U/kg)
n 3,045 4,186 2,365 1,054
Baselinea 0.27 ± 0.13 0.25 ± 0.13 0.22 ± 0.12 0.20 ± 0.12
Week 24a 0.36 ± 0.18 0.35 ± 0.19 0.35 ± 0.18 0.35 ± 0.18
Dosing frequency at baseline, n (%)
n 3,045 4,186 2,365 1,054
Once dailyb 2,815 (92.4) 3,687 (88.1) 2,205 (93.2) 962 (91.3)
Twice dailyb 222 (7.3) 492 (11.8) 157 (6.6) 91 (8.6)
Thrice dailyb 7 (0.2) 6 (0.1) 3 (0.1) 1 (0.1)
[Thrice dailyb 1 (0.0) 1 (0.0) – –
Dosing frequency at Week 24, n (%)
n 2,580 3,691 2,176 968
Once dailyb 2,160 (83.7) 2,841 (77.0) 1,705 (78.4) 733 (75.7)
Twice dailyb 337 (13.1) 729 (19.8) 383 (17.6) 180 (18.6)
Thrice dailyb 28 (1.1) 35 (0.9) 37 (1.7) 23 (2.4)
[Thrice dailyb 55 (2.1) 86 (2.3) 51 (2.3) 32 (3.3)
The mean total daily IDet dose at baseline and Week 24 is presented in units of U/day and U/kg for each group. Dosing
frequency of IDet at baseline and Week 24 is summarized and presented as once daily, twice daily, thrice daily and[thrice
daily. As this was a non-interventional study, data collection was based on the number of patients that reported dose details
at baseline and Week 24
BMI body mass index
a Data are represented as mean ± SD
b Data are represented as n (%)
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Lipid Profile
Baseline lipid levels appeared to be similar
across the four groups. Significant reductions
were noted in total cholesterol, triglyceride and
LDL cholesterol levels across all groups from
baseline to Week 24 (all p\0.001, Table 6).
There was no significant change in HDL
Table 5 Glycemic parameters, body weight and SBP at baseline and Week 24 by baseline BMI
Baseline BMI group (kg/m2)
<25.0 25.0 to <30.0 30.0 to <35.0 ‡35.0
HbA1c (%/mmol/mol)
n 1,814 3,055 1,936 871
Baseline 9.6 ± 1.8/81 ± 20 9.4 ± 1.6/79 ± 17 9.4 ± 1.4/79 ± 15 9.7 ± 1.6/83 ± 17
Week 24 7.6 ± 1.3/60 ± 14 7.3 ± 1.0/56 ± 11 7.3 ± 1.0/56 ± 11 7.5 ± 1.1/59 ± 12
Change, p -2.1 ± 1.7/-23 ± 19,
\0.001
-2.1 ± 1.6/-23 ± 17,
\0.001
-2.1 ± 1.4/-23 ± 15,
\0.001
-2.2 ± 1.5/-24 ± 16,
\0.001
FPG (mg/dL)
n 1,992 3,121 1,916 825
Baseline 205.7 ± 63.9 201.1 ± 56.7 196.2 ± 53.7 202.0 ± 53.4
Week 24 125.6 ± 35.6 126.7 ± 33.1 123.5 ± 31.7 127.5 ± 34.7
Change, p -80.0 ± 65.4,\0.001 -74.4 ± 55.6,\0.001 -72.7 ± 51.7,\0.001 -74.5 ± 53.5,\0.001
PPPG (mg/dL)
n 1,281 2,148 1,342 597
Baseline 271.7 ± 77.6 271.9 ± 73.1 260.8 ± 71.7 269.0 ± 74.5
Week 24 173.4 ± 53.7 170.6 ± 46.8 164.5 ± 44.4 170.0 ± 48.4
Change, p -98.3 ± 80.9,\0.001 -101.3 ± 73.9,\0.001 -96.3 ± 69.6,\0.001 -99.0 ± 72.3,\0.001
Body weight (kg)
n 2,373 3,442 2,044 896
Baseline 60.7 ± 8.4 74.5 ± 9.2 87.4 ± 10.3 102.2 ± 14.3
Week 24 61.8 ± 8.5 74.2 ± 9.2 86.0 ± 9.8 100.1 ± 14.2
Change, p 1.0 ± 3.2,\0.001 -0.3 ± 3.5,\0.001 -1.4 ± 4.3,\0.001 -2.2 ± 5.0,\0.001
SBP (mmHg)
n 2,201 3,116 2,040 917
Baseline 129.6 ± 17.9 133.3 ± 16.2 134.9 ± 15.5 136.8 ± 15.9
Week 24 125.5 ± 14.0 127.9 ± 17.2 128.7 ± 12.9 130.5 ± 15.0
Change, p -4.2 ± 17.6,\0.001 -5.4 ± 19.3,\0.001 -6.2 ± 15.0,\0.001 -6.2 ± 16.7,\0.001
All data are mean ± SD or as stated
BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, PPPG postprandial plasma glucose,
SBP systolic blood pressure
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cholesterol in Group I, while significant
increases were noted in the remaining three
groups (all p\0.001, Table 6).
Quality of Life
The mean EQ-5D VAS scores improved
significantly from baseline to Week 24 for all
groups (Group I, 63.4 ± 16.1 points vs.
77.1 ± 12.1 points; Group II, 60.7 ± 17.5
points vs. 77.7 ± 12.3 points; Group III,
60.2 ± 17.3 points vs. 77.4 ± 12.0 points;
Group IV, 61.3 ± 17.7 points vs. 75.7 ± 12.5
points; all p\0.001).
DISCUSSION
This sub-analysis of the A1chieve study
demonstrated the safety and efficacy of IDet
therapy, irrespective of baseline BMI status, in a
cohort of insulin-naı¨ve patients. The initiation
of IDet therapy was well-tolerated in all patient
Table 6 Lipid proﬁle at baseline and Week 24 by baseline BMI
Baseline BMI group (kg/m2)
<25.0 25.0 to <30.0 30.0 to <35.0 ‡35.0
Total cholesterol (mmol/L)
n 805 1,455 1,320 625
Baseline 5.1 ± 1.3 5.3 ± 1.2 5.4 ± 1.2 5.4 ± 1.2
Week 24 4.7 ± 0.9 4.8 ± 0.9 4.8 ± 1.0 4.9 ± 0.9
Change, p -0.4 ± 1.2,\0.001 -0.6 ± 1.1,\0.001 -0.6 ± 1.1,\0.001 -0.5 ± 1.0,\0.001
Triglycerides (mmol/L)
n 760 1,403 1,210 585
Baseline 1.9 ± 1.1 2.1 ± 1.1 2.1 ± 1.0 2.1 ± 1.0
Week 24 1.6 ± 0.8 1.7 ± 0.7 1.8 ± 0.6 1.7 ± 0.6
Change, p -0.3 ± 1.0,\0.001 -0.4 ± 0.9,\0.001 -0.4 ± 0.8,\0.001 -0.4 ± 0.8,\0.001
HDL cholesterol (mmol/L)
n 614 1,115 993 478
Baseline 1.2 ± 0.4 1.1 ± 0.4 1.1 ± 0.4 1.1 ± 0.3
Week 24 1.2 ± 0.4 1.2 ± 0.3 1.2 ± 0.4 1.2 ± 0.3
Change, p 0.0 ± 0.4, 0.167 0.0 ± 0.4,\0.001 0.1 ± 0.3,\0.001 0.1 ± 0.3,\0.001
LDL cholesterol (mmol/L)
n 623 1,129 995 491
Baseline 3.0 ± 1.0 3.1 ± 1.0 3.2 ± 1.1 3.1 ± 0.9
Week 24 2.7 ± 0.8 2.7 ± 0.9 2.7 ± 0.8 2.7 ± 0.8
Change, p -0.3 ± 1.0,\0.001 -0.4 ± 1.1,\0.001 -0.5 ± 1.0,\0.001 -0.4 ± 0.9,\0.001
All data are mean ± SD or as stated. As this was a non-interventional study, data collection was based on the number of
patients with lipid measurements at baseline and Week 24
BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein
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subgroups, stratified by baseline BMI intervals,
with only four SADRs reported in the entire
cohort of 10,650 patients.
Body weight is known to impact the
progression of T2DM with weight gain leading
to increased insulin resistance [12]. Weight loss
is the chief recommendation for overweight
and obese patients with T2DM according to the
2013 ADA Standards of Medical Care [13], and
this is also endorsed by the International
Diabetes Federation global guidelines for
T2DM [14]. Meneghini et al. [1] suggested that
T2DM patients with an HbA1c level close to the
ADA target of \7.0% (\53 mmol/mol) might
benefit from glucose-lowering therapies that
minimize weight gain. However, for patients
with very poor glycemic control [HbA1c
levels[8.0% ([64 mmol/mol)], the first
priority must be to improve glycemic control,
followed by modulating weight gain [15].
At baseline, all patient subgroups had mean
HbA1c levels[9.0% ([75 mmol/mol) with more
than half of the patients ([50.0%) in all
subgroups taking 2 OGLDs (commonly
metformin and sulfonylurea). High BMI levels
did not appear to be related to worsened
glycemic control, concordant with the
findings from the SOLVE study on the
initiation of IDet therapy [6]. All subgroups
had a mean duration of T2DM of approximately
8.0 years and a mean duration on OGLDs of
approximately 7.0 years. These findings point to
a general lack of application of international
recommendations for timely therapeutic
intensification in actual clinical practice.
However, delayed therapy intensification did
not appear to be linked with high baseline BMI.
It is known that patients with high levels of
HbA1c prior to the initiation of insulin attain
the most clinically significant improvements in
glycemic control [6]. In the current sub-
analysis, all patient subgroups experienced a
significant reduction in mean HbA1c levels by
approximately -2.1% (-23 mmol/mol).
The mean FPG and PPPG levels also
improved significantly following the start
of IDet therapy. The ADA-EASD guidelines
recommend maintaining FPG levels
at \130 mg/dL and PPPG at \180 mg/dL to
reduce the risk of micro- and macrovascular
complications [2]. Despite high mean baseline
levels of FPG and PPPG of [195 mg/dL and
[260 mg/dL, respectively, the mean values at
Week 24 met the recommended targets in all
patient subgroups. Also, the number of patients
meeting the HbA1c target level of \7.0%
(\53 mmol/mol) appeared to increase at Week
24 compared to baseline.
A significant decrease from the 4 weeks
preceding baseline to the 4 weeks preceding
the final visit was noted in the proportion of
patients reporting overall hypoglycemia in
Group I (25.0 to \30.0 kg/m2). A significant
increase from baseline to Week 24 was
witnessed in the proportion of patients
reporting overall hypoglycemia in Groups III
and IV (30.0 to\35.0 kg/m2, and C35.0 kg/m2);
however, the overall incidence of hypoglycemia
at Week 24 remained low (1.59 and 2.36 events
per patient-year, respectively). These results are
in keeping with the known safety profile of IDet
[7]. The incidence of minor and nocturnal
hypoglycemic events also remained low at the
end of the study, while only 1 event of major
hypoglycemia was reported at Week 24 in a
patient from Group IV (C35.0 kg/m2).
IDet is known to exert a beneficial effect on
weight gain and the findings from this study are
in accordance with previously reported results
from clinical trials [16, 17]. A modest,
statistically significant increase in mean body
weight (1.0 ± 3.2 kg) was noted in Group I
(\25.0 kg/m2) after 24 weeks. The mean
body weight was observed to decrease
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significantly for patients in the overweight
and obese BMI groups and greater weight
reductions were observed with higher BMI
(25.0 to \30.0 kg/m2, -0.3 ± 3.5 kg; 30.0
to \35.0 kg/m2, -1.4 ± 4.3 kg; C35.0 kg/m2,
-2.2 ± 5.0 kg) at Week 24. Results from the
TITRATE study, in which IDet was added to
OGLD regimens, also indicated that changes in
body weight from baseline after initiating IDet
treatment were related to baseline BMI [18]. In
two clinical trials, patients with higher baseline
BMI gained less weight with IDet therapy [16,
19] and this finding was also noted in a
subgroup analysis of the large, observational
PREDICTIVE study on IDet therapy [20].
High blood pressure and abnormal lipid
levels are common co-morbidities in
T2DM patients with poor glycemic control
[21]. The significant improvement in SBP
levels, especially in the overweight and obese
BMI groups (25.0 to \30.0 kg/m2, 30.0
to \35.0 kg/m2, and C35.0 kg/m2) by an
average of 5–6 mmHg, is particularly
noteworthy in light of a recent meta-analysis by
Bangalore et al. [22], wherein a reduction of SBP
below 135 mmHg was found to be associated
with a 10% reduction in all-cause mortality and a
17% reduction in the risk of stroke.
By Week 24, significant reductions in total
cholesterol, triglyceride and LDL cholesterol
were also seen across all patient subgroups.
The mean HDL cholesterol levels remained
stable in all subgroups and increased
significantly for patients in the overweight and
obese BMI groups (25.0 to\30.0 kg/m2, 30.0 to
\35.0 kg/m2, and C35.0 kg/m2) by Week 24.
Patients with T2DM often avoid the
initiation of insulin due to perceptions that
life will become more restricted [23]. Also, fear
of needles and the inconvenience of taking
daily insulin injections have been cited as major
blocks to the initiation of insulin by many
patients. However, in this sub-analysis, the
mean QoL improved significantly across all
patient subgroups. It is possible that the
patients may have experienced a sense of well-
being associated with the reductions in
glycemic endpoints and the general
improvements seen in body weight in the
higher BMI groups, and lipid and SBP levels,
together with the low incidence of
hypoglycemia.
This study had certain limitations due to its
non-interventional nature, including the
absence of a control group and the possible
lack of standardization of procedures across
sites. Data on hypoglycemic events occurring
in the preceding 4 weeks were captured
retrospectively at study visits and could have
been subjected to recall bias. Furthermore,
lifestyle and dietary information were not
tracked, so it is not possible to determine
whether any advice from the physicians or
changes initiated by the patients may have
affected the treatment outcomes.
Nevertheless, this study offered an
opportunity to investigate T2DM management
practices in a heterogeneous cohort of patients
with varying BMI status at baseline and the
results were generally concordant with the well-
known safety and efficacy of IDet therapy. In
conclusion, the results observed in this cohort
are encouraging as IDet therapy was associated
with significant improvements in glycemic
parameters, irrespective of baseline BMI status,
and also induced weight loss in overweight and
obese patients with T2DM.
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